Limits...
The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette-Guerin.

Hegazy R, Kamel M, Salem EA, Salem NA, Fawzy A, Sakr A, El-Farargy O, Nawar N, El-Atar A, Shahin AM, Hegazy A - Arab J Urol (2015)

Bottom Line: In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study.These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy.Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2/neu therapies.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Faculty of medicine, Zagazig University, Cairo, Egypt.

ABSTRACT

Objective: To investigate whether the immunohistochemical expression of p53, p63 and her2/neu is correlated with the prognosis of tumour recurrence and progression in patients with non-muscle invasive (NMI) bladder cancer.

Patients and methods: In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study. Paraffin-embedded specimens were obtained by transurethral resection of the bladder tumours. Sections on haematoxylin and eosin-stained slides were examined histologically and tumour grade was classified according to the World Health Organisation system (2004) Mostofi classification. The sections were evaluated using p63, p53 and her2/neu immunohistochemical staining before and after immunotherapy with bacille Calmette-Guerin (BCG), and patients were followed up for 36 months in the Urology Department.

Results: For tumour grade there was a significant relationship with the overexpression of p53 (P = 0.010), her2 (P = 0.025) and negativity of p63 (P = 0.025). There was no significant relationship between p53 or her2/neu overexpression and tumour stage. However, there was a significant correlation (P = 0.005) between p63 negativity and tumour stage. There was a significant relationship between p53 (P = 0.01), her2/neu (P = 0.025) overexpression and p63 negativity (P = 0.005) and tumour recurrence and progression.

Conclusion: Patients with transitional cell carcinoma who are selected for BCG treatment should preferably be positively immunoreactive for p63, but negative for both p53 and her2/neu. These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy. Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2/neu therapies.

No MeSH data available.


Related in: MedlinePlus

(A) A case of T1G2, showing a strong nuclear reaction to p53; ×400. (B): A case of T1G2, showing a weak nuclear reaction to p63; ×400.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4563013&req=5

f0005: (A) A case of T1G2, showing a strong nuclear reaction to p53; ×400. (B): A case of T1G2, showing a weak nuclear reaction to p63; ×400.

Mentions: There was no significant relationship between p53 or her2/neu overexpression and tumour stage (Fig. 1A), but there was a significant correlation (P = 0.005) between p63 overexpression and tumour stage (Fig. 1B). For tumour grading there was a significant relationship with p53 (P = 0.010), p63 (P = 0.025) and her2 (P = 0.025) overexpression. There was no significant correlation between p53, p63 or her2 overexpression and cytological examination before BCG, multifocal tumours, and association with Cis or previous tumour before BCG (Table 1). There was a significant correlation between tumour recurrence and progression and p53 (P = 0.01), p63 (P = 0.005) and her2/neu (P = 0.025) overexpression (Fig. 2A and B). Fifteen patients had a recurrence before 6 months and 12 after 6 months; only 12 had progression, three of whom died later (Table 2).


The prognostic significance of p53, p63 and her2 expression in non-muscle-invasive bladder cancer in relation to treatment with bacille Calmette-Guerin.

Hegazy R, Kamel M, Salem EA, Salem NA, Fawzy A, Sakr A, El-Farargy O, Nawar N, El-Atar A, Shahin AM, Hegazy A - Arab J Urol (2015)

(A) A case of T1G2, showing a strong nuclear reaction to p53; ×400. (B): A case of T1G2, showing a weak nuclear reaction to p63; ×400.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4563013&req=5

f0005: (A) A case of T1G2, showing a strong nuclear reaction to p53; ×400. (B): A case of T1G2, showing a weak nuclear reaction to p63; ×400.
Mentions: There was no significant relationship between p53 or her2/neu overexpression and tumour stage (Fig. 1A), but there was a significant correlation (P = 0.005) between p63 overexpression and tumour stage (Fig. 1B). For tumour grading there was a significant relationship with p53 (P = 0.010), p63 (P = 0.025) and her2 (P = 0.025) overexpression. There was no significant correlation between p53, p63 or her2 overexpression and cytological examination before BCG, multifocal tumours, and association with Cis or previous tumour before BCG (Table 1). There was a significant correlation between tumour recurrence and progression and p53 (P = 0.01), p63 (P = 0.005) and her2/neu (P = 0.025) overexpression (Fig. 2A and B). Fifteen patients had a recurrence before 6 months and 12 after 6 months; only 12 had progression, three of whom died later (Table 2).

Bottom Line: In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study.These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy.Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2/neu therapies.

View Article: PubMed Central - PubMed

Affiliation: Department of Pathology, Faculty of medicine, Zagazig University, Cairo, Egypt.

ABSTRACT

Objective: To investigate whether the immunohistochemical expression of p53, p63 and her2/neu is correlated with the prognosis of tumour recurrence and progression in patients with non-muscle invasive (NMI) bladder cancer.

Patients and methods: In all, 88 patients diagnosed with NMI transitional cell carcinoma of the bladder in a Urology Department from May 2009 to April 2014 were included in the study. Paraffin-embedded specimens were obtained by transurethral resection of the bladder tumours. Sections on haematoxylin and eosin-stained slides were examined histologically and tumour grade was classified according to the World Health Organisation system (2004) Mostofi classification. The sections were evaluated using p63, p53 and her2/neu immunohistochemical staining before and after immunotherapy with bacille Calmette-Guerin (BCG), and patients were followed up for 36 months in the Urology Department.

Results: For tumour grade there was a significant relationship with the overexpression of p53 (P = 0.010), her2 (P = 0.025) and negativity of p63 (P = 0.025). There was no significant relationship between p53 or her2/neu overexpression and tumour stage. However, there was a significant correlation (P = 0.005) between p63 negativity and tumour stage. There was a significant relationship between p53 (P = 0.01), her2/neu (P = 0.025) overexpression and p63 negativity (P = 0.005) and tumour recurrence and progression.

Conclusion: Patients with transitional cell carcinoma who are selected for BCG treatment should preferably be positively immunoreactive for p63, but negative for both p53 and her2/neu. These patients were less susceptible to recurrence and/or progression after BCG adjuvant therapy. Further studies are needed to investigate the relationship between these three markers and treatment with anti-her2/neu therapies.

No MeSH data available.


Related in: MedlinePlus